BioCentury | Feb 22, 2020
Product Development

Regenerative medicine for hearing loss makes quiet progress

While the late-stage programs for hearing loss are designed to protect cells in the inner ear, or help them recover from trauma, a growing number of early-stage therapies is aiming for a more dramatic outcome...
BioCentury | May 20, 2019
Finance

Boehringer Ingelheim, UCB venture arms seed hearing loss newco Rinri

Seven years after its first foray into hearing loss, Boehringer Ingelheim Venture Fund is investing in U.K. stem cell therapy company Rinri. On May 20, Boehringer's corporate venture fund co-led a £1.4 million ($1.8 million)...
Items per page:
1 - 2 of 2
BioCentury | Feb 22, 2020
Product Development

Regenerative medicine for hearing loss makes quiet progress

While the late-stage programs for hearing loss are designed to protect cells in the inner ear, or help them recover from trauma, a growing number of early-stage therapies is aiming for a more dramatic outcome...
BioCentury | May 20, 2019
Finance

Boehringer Ingelheim, UCB venture arms seed hearing loss newco Rinri

Seven years after its first foray into hearing loss, Boehringer Ingelheim Venture Fund is investing in U.K. stem cell therapy company Rinri. On May 20, Boehringer's corporate venture fund co-led a £1.4 million ($1.8 million)...
Items per page:
1 - 2 of 2